# An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

> **NCT06029010** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2326 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT06029010
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-31
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 2326 (ACTUAL)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029010, "An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06029010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*